• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.

    8/14/25 2:28:37 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Context Therapeutics Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    21077P108

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Avidity Partners Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,126,176.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,126,176.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,126,176.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Avidity Partners Management (GP) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,126,176.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,126,176.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,126,176.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Avidity Capital Partners Fund (GP) LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,126,176.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,126,176.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,126,176.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Avidity Capital Partners (GP) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,126,176.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,126,176.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,126,176.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Avidity Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,183,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,183,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,183,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Avidity Private Master Fund I LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,776,296.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,776,296.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,776,296.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    21077P108


    1Names of Reporting Persons

    Michael Gregory
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,126,176.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,126,176.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,126,176.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Context Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103
    Item 2. 
    (a)Name of person filing:

    Avidity Partners Management LP Avidity Partners Management (GP) LLC Avidity Capital Partners Fund (GP) LP Avidity Capital Partners (GP) LLC Avidity Master Fund LP Avidity Private Master Fund I LP Michael Gregory
    (b)Address or principal business office or, if none, residence:

    Avidity Partners Management LP 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America Avidity Partners Management (GP) LLC 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America Avidity Capital Partners Fund (GP) LP 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America Avidity Capital Partners (GP) LLC 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America Avidity Master Fund LP 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America Avidity Private Master Fund I LP 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America Michael Gregory c/o Avidity Partners Management LP 2828 N Harwood Street, Suite 1220 Dallas, Texas 75201 United States of America
    (c)Citizenship:

    Avidity Partners Management LP - Delaware Avidity Partners Management (GP) LLC - Delaware Avidity Capital Partners Fund (GP) LP - Delaware Avidity Capital Partners (GP) LLC - Delaware Avidity Master Fund LP - Cayman Islands Avidity Private Master Fund I LP - Cayman Islands Michael Gregory - United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    21077P108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Avidity Partners Management LP - 9,126,176 Avidity Partners Management (GP) LLC - 9,126,176 Avidity Capital Partners Fund (GP) LP - 9,126,176 Avidity Capital Partners (GP) LLC - 9,126,176 Avidity Master Fund LP - 5,183,700 Avidity Private Master Fund I LP - 7,776,296 Michael Gregory - 9,126,176
    (b)Percent of class:

    Avidity Partners Management LP - 9.9% Avidity Partners Management (GP) LLC - 9.9% Avidity Capital Partners Fund (GP) LP - 9.9% Avidity Capital Partners (GP) LLC - 9.9% Avidity Master Fund LP - 5.6% Avidity Private Master Fund I LP - 8.4% Michael Gregory - 9.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Avidity Partners Management LP - 0 Avidity Partners Management (GP) LLC - 0 Avidity Capital Partners Fund (GP) LP - 0 Avidity Capital Partners (GP) LLC - 0 Avidity Master Fund LP - 0 Avidity Private Master Fund I LP - 0 Michael Gregory - 0

     (ii) Shared power to vote or to direct the vote:

    Avidity Partners Management LP - 9,126,176 Avidity Partners Management (GP) LLC - 9,126,176 Avidity Capital Partners Fund (GP) LP - 9,126,176 Avidity Capital Partners (GP) LLC - 9,126,176 Avidity Master Fund LP - 5,183,700 Avidity Private Master Fund I LP - 7,776,296 Michael Gregory - 9,126,176

     (iii) Sole power to dispose or to direct the disposition of:

    Avidity Partners Management LP - 0 Avidity Partners Management (GP) LLC - 0 Avidity Capital Partners Fund (GP) LP - 0 Avidity Capital Partners (GP) LLC - 0 Avidity Master Fund LP - 0 Avidity Private Master Fund I LP - 0 Michael Gregory - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Avidity Partners Management LP - 9,126,176 Avidity Partners Management (GP) LLC - 9,126,176 Avidity Capital Partners Fund (GP) LP - 9,126,176 Avidity Capital Partners (GP) LLC - 9,126,176 Avidity Master Fund LP - 5,183,700 Avidity Private Master Fund I LP - 7,776,296 Michael Gregory - 9,126,176

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see Exhibit B attached hereto.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Avidity Partners Management LP
     
    Signature:By: Avidity Partners Management (GP) LLC, its general partner, By: /s/ Michael Gregory
    Name/Title:Michael Gregory/Managing Member
    Date:08/14/2025
     
    Avidity Partners Management (GP) LLC
     
    Signature:/s/ Michael Gregory
    Name/Title:Michael Gregory/Managing Member
    Date:08/14/2025
     
    Avidity Capital Partners Fund (GP) LP
     
    Signature:By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
    Name/Title:Michael Gregory/Managing Member
    Date:08/14/2025
     
    Avidity Capital Partners (GP) LLC
     
    Signature:/s/ Michael Gregory
    Name/Title:Michael Gregory/Managing Member
    Date:08/14/2025
     
    Avidity Master Fund LP
     
    Signature:By: Avidity Capital Partners Fund (GP) LP, its general partner, By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
    Name/Title:Michael Gregory/Managing Member
    Date:08/14/2025
     
    Avidity Private Master Fund I LP
     
    Signature:By: Avidity Capital Partners Fund (GP) LP, its general partner, By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
    Name/Title:Michael Gregory/Managing Member
    Date:08/14/2025
     
    Michael Gregory
     
    Signature:/s/ Michael Gregory
    Name/Title:Michael Gregory
    Date:08/14/2025

    Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Exhibit Information

    [Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

    Get the next $CNTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTX

    DatePrice TargetRatingAnalyst
    4/21/2025Outperform
    William Blair
    1/8/2025$4.00Mkt Outperform
    JMP Securities
    11/25/2024$9.00Buy
    D. Boral Capital
    5/16/2024$4.50Overweight
    Piper Sandler
    2/2/2022$6.00Buy
    HC Wainwright & Co.
    1/24/2022$10.00Buy
    ThinkEquity
    More analyst ratings

    $CNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lehr Martin A. bought $70,080 worth of shares (100,000 units at $0.70) (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:26:21 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer, Corp. Sec Levit Alex C. bought $11,520 worth of shares (20,000 units at $0.58), increasing direct ownership by 222% to 29,000 units (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:23:47 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Minai-Azary Jennifer Lynn bought $25,486 worth of shares (40,010 units at $0.64), increasing direct ownership by 100% to 80,010 units (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:22:20 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Context Therapeutics to Participate in Upcoming Investor Conferences

    PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025Fireside chat: Wednesday, September 3 at 10:55 AM ET in New York, NY1x1 Meetings on September 3 H.C. Wainwright 27th Annual Global Investment ConferenceFireside chat: Monday, September 8 at 3:30 PM ET in New York, NY1x1 Meetings on September 8 For additional information or to request a meeting with Context's management team during

    8/27/25 7:30:16 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

    CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. "We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 ("CLDN6") x CD3 bispecific an

    8/6/25 4:11:01 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

    Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, IL. The Phase 1 clinical trial is an open-label, d

    6/2/25 7:30:42 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    SEC Filings

    View All

    Context Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Context Therapeutics Inc. (0001842952) (Filer)

    9/2/25 7:32:00 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.

    SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    8/14/25 5:11:39 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.

    SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    8/14/25 2:28:37 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Context Therapeutics

    William Blair initiated coverage of Context Therapeutics with a rating of Outperform

    4/21/25 8:38:14 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Context Therapeutics with a new price target

    JMP Securities initiated coverage of Context Therapeutics with a rating of Mkt Outperform and set a new price target of $4.00

    1/8/25 7:37:35 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Context Therapeutics with a new price target

    D. Boral Capital initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $9.00

    11/25/24 8:20:51 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pasternak Andy

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/12/25 5:30:09 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kantoff Philip W.

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/12/25 5:28:39 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith Karen L.

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/12/25 5:27:03 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Leadership Updates

    Live Leadership Updates

    View All

    Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

    PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer ("CMO"), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors ("Board"). Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors at Adaptimmune Therapeutics plc ("Adaptimmune") and Tmunity

    5/29/25 7:30:05 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

    Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025.  "I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully int

    1/13/25 7:30:07 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

    PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. "Karen and Luke's vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. "Karen's extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in

    9/4/24 7:30:47 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Financials

    Live finance-specific insights

    View All

    Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

    CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. "We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 ("CLDN6") x CD3 bispecific an

    8/6/25 4:11:01 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

    CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We continue to advance our clinical pipeline and are pleased to have two product c

    5/7/25 4:09:57 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Full Year 2024 Operating and Financial Results

    CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a s

    3/20/25 4:22:37 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 4:52:28 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care